AstraZeneca Says Mylan Can't Sell Cancer Generic Till 2019
AstraZeneca Pharmaceuticals LP on Friday slapped Mylan Institutional LLC with a Delaware federal suit seeking to block Mylan from selling a generic version of the breast cancer drug Faslodex just a...To view the full article, register now.
Already a subscriber? Click here to view full article